Ultragenyx Pharmaceutical

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Trade Ultragenyx Pharmaceutical 24 hours a day, five days a week on Robinhood.

Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.

About RARE

Ultragenyx Pharmaceutical, Inc. is a biopharmaceutical company, which engages in the identification, acquisition, development, and commercialization of novel products for the treatment of genetic diseases. Its products include Crysvita, Mepsevii, Dojolvi, and Evkeeza. 

CEO
Emil D. Kakkis
CEOEmil D. Kakkis
Employees
1,371
Employees1,371
Headquarters
Novato, California
HeadquartersNovato, California
Founded
2010
Founded2010
Employees
1,371
Employees1,371

RARE Key Statistics

Market cap
2.31B
Market cap2.31B
Price-Earnings ratio
-3.83
Price-Earnings ratio-3.83
Dividend yield
Dividend yield
Average volume
1.48M
Average volume1.48M
High today
$24.12
High today$24.12
Low today
$23.26
Low today$23.26
Open price
$23.68
Open price$23.68
Volume
1.10M
Volume1.10M
52 Week high
$42.37
52 Week high$42.37
52 Week low
$18.29
52 Week low$18.29

Stock Snapshot

The current Ultragenyx Pharmaceutical(RARE) stock price is $23.39, with a market capitalization of 2.31B. The stock trades at a price-to-earnings (P/E) ratio of -3.83.

During the trading session on 2026-05-24, Ultragenyx Pharmaceutical(RARE) shares reached a daily high of $24.12 and a low of $23.26. At a current price of $23.39, the stock is +0.6% higher than the low and still -3.0% under the high.

Trading activity shows a volume of 1.1M, compared to an average daily volume of 1.48M.

Over the past 52 weeks, Ultragenyx Pharmaceutical(RARE) stock has traded between a high of $42.37 and a low of $18.29.

Over the past 52 weeks, Ultragenyx Pharmaceutical(RARE) stock has traded between a high of $42.37 and a low of $18.29.

RARE News

Investing.com 4d
Cantor Fitzgerald raises Ultragenyx stock price target on therapy outlook - Investing.com

...

Cantor Fitzgerald raises Ultragenyx stock price target on therapy outlook - Investing.com
TipRanks 6d
Ultragenyx Shareholders Approve Incentive Plan, Elect Directors

Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions Discover top-performing stock ideas and upgrade to a portfolio of mark...

Analyst ratings

89%

of 19 ratings
Buy
89.5%
Hold
10.5%
Sell
0%

People also own

Based on the portfolios of people who own RARE. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.